In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2014-11-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.04124-14PMID 25385112PMCID PMC4291388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transferable vancomycin resistance in a community-associated MRSA lineage.

  2014cited by this paper
• Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae

  2014cited by this paper
• In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

  2014cited by this paper
• Clinical and Laboratory Standards Institute.

  2013cited by this paper
• Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain.

  2012influential reference
• Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7 2007

  2012cited by this paper
• Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone

  2011cited by this paper
• Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.

  2010cited by this paper
• Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

  2010cited by this paper
• Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds

  2006cited by this paper
• Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

  2006cited by this paper
• Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline

  2006cited by this paper
• Postantibiotic Effect of DX-619 against 16 Gram-Positive Organisms

  2005cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Postantibiotic Effects of Grepafloxacin Compared to Those of Five Other Agents against 12 Gram-Positive and -Negative Bacteria

  2000cited by this paper
• Activities of Trovafloxacin Compared with Those of Other Fluoroquinolones against Purified Topoisomerases and gyrA and grlA Mutants ofStaphylococcus aureus

  1999cited by this paper
• Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC

  1998cited by this paper
• GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin

  1996cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

  1990cited by this paper
• In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia

  1990cited by this paper
• [Antimicrobial combinations].

  1972cited by this paper
• Manual of Clinical Microbiology

  1970cited by this paper
• The estimation of the bactericidal power of the blood

  1938cited by this paper

• Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks

  2026cites this paper
• Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

  2024cites this paper
• A molecular and phenotypic analysis of the prevalence and patterns of antimicrobial resistance in Neisseria gonorrhoeae isolates from Kwazulu Natal, South Africa

  2024cites this paper
• Efficacy of Zoliflodacin, a Spiropyrimidinetrione Antibiotic, Against Gram-Negative Pathogens

  2024cites this paper
• Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target

  2024cites this paper
• Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting

  2024cites this paper
• Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance

  2024cites this paper
• Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance.

  2023cites this paper
• In Silico and In Vitro Identification of 1,8-Dihydroxy-4,5-dinitroanthraquinone as a New Antibacterial Agent against Staphylococcus aureus and Enterococcus faecalis

  2023cites this paper
• An Erythrocyte Membrane‐Derived Nanosystem for Efficient Reversal of Endothelial Injury in Sepsis

  2023cites this paper
• Emerging threat of antimicrobial resistance in Neisseria gonorrhoeae: pathogenesis, treatment challenges, and potential for vaccine development

  2023cites this paper
• Stimulating Transcription in Antibiotic-Tolerant Escherichia coli Sensitizes It to Fluoroquinolone and Nonfluoroquinolone Topoisomerase Inhibitors

  2023cites this paper
• Application of Principal Component Analysis (PCA) to the Evaluation and Screening of Multiactivity Fungi

  2022cites this paper
• Antimicrobial Resistance of Neisseria gonorrhoeae in Sub-Saharan Populations

  2022cites this paper
• Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones

  2022cites this paper
• Relevance of antibiotic overuse: Covid 19: Super gonorrhea: A review

  2021cites this paper
• Non-quinolone Inhibitors of the Bacterial DNA Gyrase

  2021cites this paper
• Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults

  2021cites this paper
• Susceptibility Trends of Zoliflodacin against Multidrug-Resistant <italic toggle='yes'>Neisseria gonorrhoeae</italic> Clinical Isolates in Nanjing, China, 2014 to 2018

  2021cites this paper
• Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant Staphylococcus aureus.

  2021cites this paper
• Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.

  2021cites this paper
• GyrB inhibitors as potential antibacterial agents: a review

  2021cites this paper
• Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions

  2021cites this paper
• Recent advances in antibacterial agents.

  2021cites this paper
• Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors.

  2020cites this paper
• Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018

  2020cites this paper
• Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)

  2020cites this paper
• Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors

  2020influential citation
• The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

  2020cites this paper
• Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug resistant isolates.

  2020cites this paper
• New Topoisomerase Inhibitors: Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon tolC Inactivation and Differentiating Their Efflux Pump Substrate Nature

  2020cites this paper
• University of Birmingham The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae

  2020cites this paper
• Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria.

  2019cites this paper
• Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea.

  2019cites this paper
• Spirocyclic tetramates by sequential Knoevenagel and [1,5]-prototropic shift.

  2019cites this paper
• Bacterial Type II Topoisomerases and Target-Mediated Drug Resistance

  2018cites this paper
• In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains

  2018cites this paper
• Imidazopyrazinones (IPYs): Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones.

  2018cites this paper
• Topoisomerases as anticancer targets.

  2018cites this paper
• DNA Topoisomerases as Targets for Antibacterial Agents.

  2018cites this paper
• New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.

  2018cites this paper
• Future Prospects for Neisseria gonorrhoeae Treatment

  2018influential citation
• Diastereoselective and Enantioselective Synthesis of Barbiturate-Fused Spirotetrahydroquinolines via Chiral Palladium(0)/Ligand Complex Catalyzed [4 + 2] Cycloaddition of Vinyl Benzoxazinanones with Barbiturate-Based Olefins.

  2018cites this paper
• Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

  2018cites this paper
• Single-dose Pharmacokinetics , Excretion , and Metabolism of Zoliflodacin , a 1 Novel Spiropyrimidinetrione Antibiotic , in Healthy Volunteers 2

  2018cites this paper
• Optimization of Process Parameters for Chitinase Production by a Marine Aspergillus Flavus MK20

  2018cites this paper
• Neisseria gonorrhoeae: testing, typing and treatment in an era of increased antimicrobial resistance

  2017cites this paper
• New Horizons in Mycoplasma genitalium Treatment

  2017cites this paper
• Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?

  2017cites this paper
• Sexually transmitted infections: challenges ahead.

  2017cites this paper
• Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase

  2017cites this paper
• Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914.

  2017cites this paper
• Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic

  2017cites this paper
• Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines

  2017cites this paper
• New Drugs and Emerging Leads in Antibacterial Drug Discovery

  2017cites this paper
• Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium

  2017cites this paper
• Targeting bacterial topoisomerases: how to counter mechanisms of resistance.

  2016cites this paper
• Synthesis, Solvatochromism, Antibacterial Activity and Dyeing Performance of Tricyanofuran‐Hydrazone Analogues

  2016cites this paper
• Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century

  2016cites this paper
• Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

  2016cites this paper
• New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae

  2016cites this paper
• Exploring the active site of the Streptococcus pneumoniae topoisomerase IV–DNA cleavage complex with novel 7,8-bridged fluoroquinolones

  2016cites this paper
• Mode Of Inhibition of a novel DNA gyrase inhibitor with activity against Neisseria gonorrhoeae Inhibition of Neisseria gonorrhoeae type II Topoisomerases by the Novel Spiropyrimidinetrione AZD 0914 * #

  2015cites this paper
• In Vitro Activity of AZD 0914 , a Novel Bacterial DNA Gyrase / Topoisomerase IV Inhibitor , against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

  2015cites this paper
• Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

  2015cites this paper
• In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas

  2015cites this paper
• Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.

  2015cites this paper
• In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

  2015cites this paper
• Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914*

  2015cites this paper
• High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014

  2015cites this paper
• Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin

  2015cites this paper
• Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

  2015cites this paper
• Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae

  2015cites this paper
• Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge

  2015cites this paper
• Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914).

  2015cites this paper
• Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)

  2015cites this paper
• Characterization of the novel DNA gyrase inhibitor AZD 0914 : Low resistance potential 1 and lack of cross-resistance in Neisseria gonorrhoeae . 2 3 4 5 6

  2014cites this paper
• Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae

  2014cites this paper